Europe struggles to meet the challenges posed by PGD patients travelling abroad

Lyon, France -- A new study has shown that increasing numbers of couples are travelling abroad for preimplantation genetic diagnosis (PGD), and that the main reason for this cross-border movement is the legal position in patients countries of origin.

Mr James Lawford Davies, a solicitor specialising in reproductive and genetic technologies, told the 23rd annual meeting of the European Society of Human Reproduction and Embryology today (Monday 2 July) that the main reason couples travelled to other countries was because PGD was banned in their own. However, this led to concerns over how referrals were made, whether or not the referral itself might be unlawful, and the quality (or even the existence) of counselling, medical advice, support, monitoring and follow-up for families and their children. Other reasons for travelling abroad included the quality of the treatment, test availability, expertise in certain diseases, cost and length of waiting lists in their home countries.

This is the first EU-wide study of provision and regulation of PGD, a technique for testing embryos fertilised in the laboratory for specific genetic or sex-linked disorders such as cystic fibrosis or Duchenne muscular dystrophy. Only unaffected embryos are transferred to the womans uterus, thus avoiding the possible need for a pregnancy termination when the defect is picked up at a later stage.

The study [1] was launched by the European Commission after a workshop organised jointly by the Institute for Prospective Technological Studies (IPTS) of the European Commission's Joint Research Centre (JRC), ESHRE and the European Society of Human Genetics (ESHG) revealed that little was know about the extent to which couples crossed national boundaries to gain access to treatment and what different regulatory frameworks for PGD existed in Member States. Mr Lawford Davies, who lectures in law and medicine at the Institute for Human Genetics at Newcastle University and i

Contact: Emma Mason
European Society for Human Reproduction and Embryology

Page: 1 2 3 4

Related biology news :

1. European Science Foundations Forward Look reaches out beyond the endless frontiers
2. Census of Marine Life historians detail collapse of bluefin tuna population off northern Europe
3. The UAB heads a European research project on proteases and pathological processes
4. Journalists can register now for ECCO 14 -- the European Cancer Conference
5. Major study predicts grim future for Europes seas
6. Climate changes brews trouble for marine life in European Seas, Marine Board-ESF report says
7. Mellow in Europe, crazy in America
8. Early Europeans unable to stomach milk
9. European launch of International Polar Year 2007-2008
10. IDIBAPS participates in European Network on antibiotic resistances and hospital infections
11. European approval of HIV drug darunavir will provide a potent new option with Fuzeon

Post Your Comments:

(Date:8/26/2020)... ... August 25, 2020 , ... ... targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in ... 3 VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate to ...
(Date:8/21/2020)... , ... August 18, 2020 , ... ... cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ... lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, ... have entered into license agreements with Housey Pharma’s HMI subsidiary to gain access ... J&J have annual Research and Development spending in excess of US $10 billion. ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... August 13, 2020 ... ... 4254 on its annual Inc. 5000 list, the most prestigious ranking of the ... successful companies within the American economy’s most dynamic segment—its independent small businesses. Intuit, ...
(Date:8/3/2020)... , ... August 03, 2020 , ... ... today announced Jim Corrigan, President and CEO has been named one of the ... cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how they ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
(Date:7/22/2020)... TORONTO (PRWEB) , ... July 22, 2020 , ... Join ... and John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... is the regulating body in China for drugs and medical devices. Specifically, for medical ...
Breaking Biology Technology:
Cached News: